Verastem IncNASDAQ:VSTM
- LAST PRICE5.3400
- TODAY'S CHANGE (%)0.7700 (16.8490%)
- Bid / Lots5.3000/ 1
- Ask / Lots5.4000/ 3
- Open / Previous Close4.6100 / 4.5700
- Day Range
- 52 Week Range
- Volume1,538,535
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VSTM |
|---|---|---|
| 09:32 ET | 10368 | 4.64 |
| 09:33 ET | 2181 | 4.63 |
| 09:35 ET | 12758 | 4.835 |
| 09:37 ET | 18937 | 4.85 |
| 09:39 ET | 22780 | 4.8606 |
| 09:42 ET | 9879 | 4.81 |
| 09:44 ET | 7387 | 4.8 |
| 09:46 ET | 3121 | 4.77 |
| 09:48 ET | 5248 | 4.745 |
| 09:50 ET | 15085 | 4.835 |
| 09:51 ET | 4759 | 4.87 |
| 09:53 ET | 5630 | 4.895 |
| 09:55 ET | 5922 | 4.86 |
| 09:57 ET | 1700 | 4.84 |
| 10:00 ET | 8126 | 4.86 |
| 10:02 ET | 1091 | 4.8566 |
| 10:04 ET | 16581 | 4.95 |
| 10:06 ET | 14347 | 4.97 |
| 10:08 ET | 4689 | 4.97 |
| 10:09 ET | 4600 | 4.97 |
| 10:11 ET | 45026 | 5.005 |
| 10:13 ET | 9363 | 5.01 |
| 10:15 ET | 8322 | 5.05 |
| 10:18 ET | 19550 | 5.02 |
| 10:20 ET | 32115 | 4.93 |
| 10:22 ET | 26696 | 4.9025 |
| 10:24 ET | 25729 | 4.84 |
| 10:26 ET | 2078 | 4.84 |
| 10:27 ET | 6080 | 4.8045 |
| 10:29 ET | 10795 | 4.82 |
| 10:31 ET | 5338 | 4.845 |
| 10:33 ET | 5416 | 4.85 |
| 10:36 ET | 5867 | 4.83 |
| 10:38 ET | 4782 | 4.83 |
| 10:40 ET | 8647 | 4.85 |
| 10:42 ET | 1825 | 4.875 |
| 10:44 ET | 7578 | 4.925 |
| 10:45 ET | 2008 | 4.92 |
| 10:47 ET | 365 | 4.92 |
| 10:49 ET | 775 | 4.91 |
| 10:51 ET | 600 | 4.955 |
| 10:54 ET | 7029 | 4.935 |
| 10:56 ET | 462 | 4.93 |
| 10:58 ET | 11417 | 4.99 |
| 11:00 ET | 4911 | 4.985 |
| 11:02 ET | 126320 | 5.03 |
| 11:03 ET | 5553 | 5.025 |
| 11:05 ET | 4756 | 5.06 |
| 11:07 ET | 13232 | 5.06 |
| 11:09 ET | 8368 | 5.04 |
| 11:12 ET | 14301 | 5.0712 |
| 11:14 ET | 32273 | 5.155 |
| 11:16 ET | 11441 | 5.205 |
| 11:18 ET | 11254 | 5.1393 |
| 11:20 ET | 6069 | 5.12 |
| 11:21 ET | 16330 | 5.07 |
| 11:23 ET | 8661 | 5.06 |
| 11:25 ET | 3811 | 5.0888 |
| 11:27 ET | 1762 | 5.095 |
| 11:30 ET | 9528 | 5.105 |
| 11:32 ET | 6500 | 5.105 |
| 11:34 ET | 19166 | 5.17 |
| 11:36 ET | 15036 | 5.135 |
| 11:38 ET | 1701 | 5.12 |
| 11:39 ET | 3254 | 5.08 |
| 11:41 ET | 1475 | 5.06 |
| 11:43 ET | 2302 | 5.0501 |
| 11:45 ET | 1847 | 5.08 |
| 11:48 ET | 1800 | 5.065 |
| 11:50 ET | 3860 | 5.05 |
| 11:52 ET | 13772 | 5 |
| 11:54 ET | 6718 | 5.07 |
| 11:56 ET | 3840 | 5.075 |
| 11:57 ET | 650 | 5.09 |
| 11:59 ET | 9900 | 5.045 |
| 12:01 ET | 7223 | 5.055 |
| 12:03 ET | 2761 | 5.04 |
| 12:06 ET | 2398 | 5.06 |
| 12:08 ET | 3010 | 5.055 |
| 12:10 ET | 1370 | 5.05 |
| 12:12 ET | 800 | 5.065 |
| 12:14 ET | 7215 | 5.08 |
| 12:15 ET | 4696 | 5.0976 |
| 12:17 ET | 38703 | 5.13 |
| 12:19 ET | 14343 | 5.145 |
| 12:21 ET | 15679 | 5.195 |
| 12:24 ET | 12063 | 5.195 |
| 12:26 ET | 22922 | 5.195 |
| 12:28 ET | 4348 | 5.215 |
| 12:30 ET | 1600 | 5.215 |
| 12:32 ET | 9032 | 5.245 |
| 12:33 ET | 13907 | 5.24 |
| 12:35 ET | 2146 | 5.24 |
| 12:37 ET | 56796 | 5.325 |
| 12:39 ET | 19611 | 5.33 |
| 12:42 ET | 36365 | 5.4 |
| 12:44 ET | 8926 | 5.4258 |
| 12:46 ET | 15479 | 5.4 |
| 12:48 ET | 60803 | 5.44 |
| 12:50 ET | 3556 | 5.43 |
| 12:51 ET | 15408 | 5.43 |
| 12:53 ET | 8921 | 5.48 |
| 12:55 ET | 98630 | 5.405 |
| 12:57 ET | 17572 | 5.4 |
| 01:00 ET | 85705 | 5.34 |
Nov 26, 2024
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference, from 7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
Nov 6, 2024
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates, from 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones*DJ Verastem 3Q Loss/Shr 60c >VSTM, from 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
Oct 31, 2024
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer, from 4:01PM ET on Thursday Oct 31, 2024 by Dow Jones
4:01PM ET on Thursday Oct 31, 2024 by Dow JonesVerastem Oncology to Participate in Upcoming Investor Conferences, from 7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Verastem Inc | 203.4M | -1.7x | --- |
XBiotech Inc | 207.6M | -7.1x | --- |
Checkpoint Therapeutics Inc | 209.0M | -3.1x | --- |
Onkure Therapeutics Inc | 196.9M | -1.3x | --- |
Zura Bio Ltd | 195.9M | -5.3x | --- |
Instil Bio Inc | 193.8M | -2.3x | --- |
Company Information
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).
Contact Information
- Headquarters
- 117 Kendrick Street, Suite 500CAMBRIDGE, MA, United States 02494
- Phone
- 781-292-4200
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- Daniel Paterson
- Vice President - Finance, Corporate Controller
- Daniel Calkins
- Independent Director
- Paul Bunn
- Independent Director
- Anil Kapur
- Independent Director
- Michelle Robertson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $203.4M |
|---|---|
Revenue (TTM) | $10.0M |
Shares Outstanding | 44.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.15 |
EPS | $-3.18 |
Book Value | $3.11 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 20.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,145.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
